Joseph A. Bovi

Joseph A. Bovi

Auto-generated profile, based on publicly available information

Joseph A. Bovi

Medical College of Wisconsin, Milwaukee, WI

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
HNH.S. Nguyen
H.S. Nguyen
NMN. Milbach
N. Milbach
SHS.L. Hurrell
S.L. Hurrell
ECE. Cochran
E. Cochran
JCJ. Connelly
J. Connelly
PLPeter S. LaViolette
Peter S. LaViolette
BACKGROUND AND PURPOSE: Patients with recurrent glioblastoma often exhibit regions of diffusion restriction following the initiation of bevacizumab therapy. Studies suggest that these regions represent either diffusion-restricted necrosis or hypercellular tumor. This study explored postmortem brain specimens and a population analysis of overall survival to determine the identity and implications of such lesions. MATERIALS AND METHODS: Postmortem examinations were performed on 6 patients with recurrent glioblastoma on bevacizumab with progressively growing regions of diffusion restriction. ADC values were extracted from regions of both hypercellular tumor and necrosis. A receiver operating characteristic analysis was performed to define optimal ADC thresholds for differentiating tissue types. A retrospective population study was also performed comparing the overall survival of 64 patients with recurrent glioblastoma treated with bevacizumab. Patients were separated into 3 groups: no diffusion restriction, diffusion restriction that appeared and progressed within 5 months of bevacizumab initiation, and delayed or stable diffusion restriction. An additional analysis was performed assessing tumor O6-methylguanine-DNA-methyltransferase methylation. RESULTS: The optimal ADC threshold for differentiation of hypercellularity and necrosis was 0.736 × 10−3mm2/s. Progressively expanding diffusion restriction was pathologically confirmed to be coagulative necrosis surrounded by viable tumor. Progressive lesions were associated with the worst overall survival, while stable lesions showed the greatest overall survival (P < .05). Of the 40% of patients with O6-methylguanine-DNA-methyltransferase methylated tumors, none developed diffusion-restricted lesions. CONCLUSIONS: Progressive diffusion-restricted lesions were pathologically confirmed to be coagulative necrosis surrounded by viable tumor and associated with decreased overall survival. Stable lesions were, however, associated with increased overall survival. All lesions were associated with O6-methylguanine-DNA-methyltransferase unmethylated tumors.

1 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JMJennifer K Matsui
Jennifer K Matsui
HPHaley K. Perlow
Haley K. Perlow
CBCyril Baiyee
Cyril Baiyee
ARAlex R. Ritter
Alex R. Ritter
MMMark V. Mishra
Mark V. Mishra
Joshua PalmerJoshua Palmer
Joshua Palmer
Brain metastases (BMs) account for a disproportionately high percentage of cancer morbidity and mortality. Historically, studies have focused on improving survival outcomes, and recent radiation oncology clinical trials have incorporated HRQOL and cognitive assessments. We are now equipped with a battery of assessments in the radiation oncology clinic, but there is a lack of consensus regarding how to incorporate them in modern clinical practice. Herein, we present validated assessments for BM patients, current recommendations for future clinical studies, and treatment advances that have improved HRQOL and cognitive outcomes for BM patients.

27 June 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
JBJoseph A. Bovi
Joseph A. Bovi
MPMelissa A. Prah
Melissa A. Prah
ARAmber A. Retzlaff
Amber A. Retzlaff
KSKathleen M. Schmainda
Kathleen M. Schmainda
JCJennifer M. Connelly
Jennifer M. Connelly
CSChristopher J. Schultz
Christopher J. Schultz
Dismal prognosis and limited treatment options for recurrent high-grade glioma have provoked interest in various forms of reirradiation. Pulsed reduced dose rate radiation therapy (pRDR) is a promising technique that exploits low-dose hyper-radiosensitivity of proliferating tumor cells while sparing adjacent nonproliferating normal brain tissue. Large radiation treatment volumes can thus be used to target both contrast-enhancing and FLAIR abnormalities thought to harbor recurrent gross and microscopic disease, respectively. The aim of this retrospective study was to determine whether the addition of pRDR to bevacizumab improves survival over bevacizumab alone for recurrent high-grade glioma. Eighty patients with recurrent high-grade glioma were included in this study; 47 patients received bevacizumab monotherapy (BEV), and 33 patients received pRDR with bevacizumab (BEV/pRDR). Progression-free survival (PFS) and overall survival were compared between the BEV and BEV/pRDR groups. Regression analysis was performed to identify and control for confounding influences on survival analyses. Significant (P <.05) advantages in PFS (12 vs 4 months; hazard ratio = 2.37) and OS (16 vs. 9 months; hazard ratio = 1.68) were observed with BEV/pRDR compared with BEV alone. This retrospective analysis suggests that treatment with pRDR in addition to bevacizumab could significantly prolong PFS and overall survival compared with bevacizumab alone for recurrent high-grade glioma.

10 November 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VGVinai Gondi
Vinai Gondi
SPStephanie L. Pugh
Stephanie L. Pugh
MMMinesh p Mehta
Minesh p Mehta
JWJeffrey S. Wefel
Jeffrey S. Wefel
WTWolfgang A. Tomé
Wolfgang A. Tomé
FOFor The Nrg Oncology
For The Nrg Oncology
PURPOSE: Hippocampal avoidance (HA) during therapeutic whole-brain radiotherapy reduces the risk of neurocognitive function (NCF) toxicity in patients with brain metastasis. This trial hypothesized that HA during prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC) leads to noninferior intracranial relapse (ICR) and reduction in NCF toxicity. METHODS: This randomized phase II/III trial enrolled patients with SCLC, no brain metastases, and response to chemotherapy. The primary end points were 12-month ICR (noninferiority design, randomized phase II) and 6-month Hopkins Verbal Learning Test–Revised (HVLT-R) Delayed Recall (DR) failure (phase III). Secondary end points were failure in any NCF test, health-related quality of life (HRQOL), overall survival (OS), and toxicity. RESULTS: From December 2015 to June 2022, 393 patients were randomly assigned. The median age was 64 years. Stage and memantine usage were balanced. The median follow-up was 17.0 months (all patients) and 30.8 months (alive patients). HA-PCI had noninferior 12-month ICR rate (PCI 14.8% v HA-PCI 14.7%, P < .0001). Six-month HVLT-R DR deterioration was not significantly different (PCI 30.0% v HA-PCI 25.5%, P = .28). Addition of HA to PCI reduced the risk of failure in any NCF test (adjusted hazard ratio [HR], 0.78; 95% CI [0.61 to 0.99]; P = .039). Addition of HA to PCI was not associated with longitudinal change in any HRQOL domain. There were no differences in OS (adjusted HR, 0.88 [95% CI, 0.67 to 1.14]; P = .33) or grade ≥3 toxicity (PCI 31.4% v HA-PCI 30.7%, P = .88). CONCLUSION: Although the study did not meet its primary end point of DR preservation, HA during PCI reduces the risk of overall neurocognitive toxicity with noninferior ICR risk and similar survival.

2 December 2011 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
JBJoseph A. Bovi
Joseph A. Bovi
JWJulia White
Julia White

9 April 2022 in JAMIA Open
Verified
Journal Article
Open access
PDF file
KLKatie Livingston
Katie Livingston
JBJoseph Bovi
Joseph Bovi
A novel approach of department-focused electronic health record (EHR) training was implemented to improve efficiency and time management of EHR use. Based off baseline log data, 5 in-person training sessions were designed, focusing on the common inefficiencies of 6 chosen participants. Log data of 4 key metrics and 2 efficiency scores were analyzed 4 months post-training. A survey was conducted to assess self-reported EHR competence. Individually, several participants had improved efficiency scores. There was a reduced average time spent in the inbox per day, in notes per dictation, and in notes per day. This translated to an average of 8.9 min saved per day (range 0–29.1 min/day) and 37.1 hours saved per year (range 0–116.2 hours/year). From the post-training surveys, all participants felt more efficient in their use of the EHR. This study demonstrates an example of department-focused EHR training and log-based analysis improving time management and efficiency.